It was recently reported that levels of plasma
IgG antibodies against
peptide antigens derived from
proteins encoded by
schizophrenia-associated genes are altered in individuals with
schizophrenia treated with
antipsychotics. This study aimed to replicate the initial finding in
antipsychotic-naïve patients with first-episode
schizophrenia and to explore the possible mechanism by which immune tolerance of B cells may be altered in this disease. A total of 408 case-control plasma samples were collected for analysis of circulating
IgG antibodies against fragments derived from TCF4, TSNARE1, ZNF804A, TRANK1, ERCC4, DPYD and CD25 using an in-house ELISA. The Mann-Whitney U-test revealed that patients with
schizophrenia had a significant change in plasma anti-TSNARE1 and anti-CD25
IgG levels; male patients mainly contributed to the increased levels of anti-TSNARE1
IgG and anti-CD25
IgG. Receiver operating characteristic (ROC) curve analysis revealed that the anti-TSNARE1
IgG assay had an area under the ROC curve of 0.625 with a sensitivity of 15.7% and a specificity of 95.2%. Work on a B-cell model revealed that TRANK1-derived
antigen treatments could enhance the proportions of CD83+ cells and apoptotic B cells when compared with TSNARE1-derived
antigen and vehicle treatment. We conclude that there is a gender difference in autoimmune responses in
schizophrenia and suggest that anti-TSNARE1
IgG may be indicative of
schizophrenia in a subgroup of male patients.